Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Sandro Pignata, Michael Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Cagatay Taskiran, Charles Anderson, Sakari Hietanen, Tashanna Myers, Radoslaw Madry, Lyndsay Willmott, Alain Lortholary, Jessica Thomes-Pepin, Carol Aghajanian, Carolyn McCourt, Ashley Stuckey, Xiaohua Wu, Shin Nishio, Larry J. Copeland, Yvette HeLuciana Molinero, Sheetal Patel, Yvonne G. Lin, Victor K. Khor, Kathleen N. Moore

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences